| 我看大家都没有问这个问题 Frazier and Mosteller assert that medical research could be improved by a move toward larger, simpler clinical Line
trials of medical treatments. Currently,
(5)
researchers collect far more background
information on patients than is strictly required for their trials—substantially more than hospitals collect—thereby escalating costs of data collection, storage, and (10)
analysis. Although limiting information
collection could increase the risk that researchers will overlook facts relevant to a study, Frazier and Mosteller contend that such risk, never entirely eliminable (15)
from research, would still be small in most
studies. Only in research on entirely new treatments are new and unexpected variables likely to arise. Frazier and Mosteller propose not (20)
only that researchers limit data collection
on individual patients but also that researchers enroll more patients in clinical trials, thereby obtaining a more representative sample of the total population with (25)
the disease under study. Often researchers
restrict study participation to patients who have no ailments besides those being studied. A treatment judged successful under these ideal conditions can then (30)
be evaluated under normal conditions.
Broadening the range of trial participants, Frazier and Mosteller suggest, would enable researchers to evaluate a treatment’s efficacy for diverse patients under (35)
various conditions and to evaluate its
effectiveness for different patient subgroups. For example, the value of a treatment for a progressive disease may vary according to a patient’s stage of (40)
disease. Patients’ ages may also affect
a treatment’s efficacy.
GWD-8-Q5 :
The author mentions patients’ ages(line 40) primarily in order to A identify the most critical variable differentiating subgroups of patients
B cast doubt on the advisability of implementing Frazier and Mosteller’s proposals about medical research
C indicate why progressive diseases may require different treatments at different stages
D illustrate a point about the value of enrolling a wide range of patients in clinical trials
E substantiate an argument about the problems inherent in enrolling large numbers of patients in clinical trials
-------------------------------------------------------------------------------- answer: D 我现在也认同D是没有问题得,但是为什么C不对那,难道C只是例子里面得一个小的方面,而D中说的范围更大? 谢谢 | 
